19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
In response to the #MeToo movement, a number of states have adopted legislation addressing sexual ha...
Read More >
The Supreme Court of Ohio recently held that R.C. § 2305.131, the real property construction of repo...
Read More >
On October 2, 2020, the Small Business Administration (SBA) published guidance on when SBA consent m...
Read More >
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceutica...
Read More >
This Interim Rule follows the Proposed Rule on filing fees published by the Committee on March 9, 20...
Read More >
New infrastructure projects will be an important part of Canada's recovery from the COVID-19 crisis,...
Read More >